Lui Alfred Fu Kong - 03 Jan 2022 Form 4 Insider Report for Emmaus Life Sciences, Inc. (EMMA)

Reporting relationship: Director
Issuer ticker: EMMA
Reported as of: 03 Jan 2022
Net transaction value: +$15,800
SEC form: 4
Accepted by SEC: 05 Jan 2022, 15:33:27 UTC
Prior SEC filing: 30 Nov 2021
Source filing: View source filing
Reporting owner signature: Alfred Lui, M.D.

Key filing fact

Lui Alfred Fu Kong filed Form 4 for Emmaus Life Sciences, Inc. (EMMA) on 05 Jan 2022.

Key facts

This page summarizes Lui Alfred Fu Kong's Form 4 filing for Emmaus Life Sciences, Inc. (EMMA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jan 2022, 15:33.

Change

Previous filing in this sequence was filed on 30 Nov 2021.
Current net transaction value: +$15,800.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EMMA transaction

Common stock, $0.001 par value

Purchase

Transaction value: $15,800
Shares: +10,000
Change %
Price: $1.58^*
Shares after: 10,000
Date: 03 Jan 2022
Ownership: Direct
Footnotes: F1

EMMA holding

Common stock, $0.001 par value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 32,358
Date: 03 Jan 2022
Ownership: Alfred and Janet Lui Family Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.65, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1).